Literature DB >> 6343226

Are increased IgE-levels a signal of an acute graft-versus-host reaction?

O Ringdén, U Persson, S G Johansson.   

Abstract

IgE-levels are markedly elevated following bone-marrow transplantation in patients with and without GVHD. In patients with GVHD, there is a significant correlation between the timing of the IgE-increase and the appearance of clinical GVHD (p less than 0.01). The highest IgE-level (8000 kU/l) was noted in a recipient of a syngeneic graft. During the IgE-peak, the serum from this patient contained low concentrations of IgE reacting with several tested allergens as well as for the hapten TNP, which indicated polyclonal activation. In a patient with a known allergy to animal danders, RAST tests were positive against dog and cat both before and six weeks after total body irradiation and transplantation with marrow from a non-allergic donor. A slight increase in the amount of allergen-specific, IgE-antibodies was seen during the increase in total IgE. A non-allergic patient was transplanted with marrow from a donor allergic to timothy. Timothy-specific, IgE-antibodies were detected immediately after transplantation but they disappeared within a few days and could not be detected during the period of increase in total IgE. We believe that the IgE-elevation seen after conditioning with cytotoxic drugs and total body irradiation in BMT-patients is a polyclonal response in host B-cells induced during an acute, GVHR and influenced by disturbed regulatory T-cells. Lymphocytes from patients with acute GVHD had unusually large numbers of IgG/PFC in vitro after stimulation with staph. aureus Cowan 1 (p less than 0.001), which may reflect a clonal expansion of responsive B-cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6343226     DOI: 10.1111/j.1600-065x.1983.tb01068.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  8 in total

Review 1.  In vitro assays for immunoglobulin E. Methodology, indications, and interpretation.

Authors:  S G Johansson; L Yman
Journal:  Clin Rev Allergy       Date:  1988

2.  Clinical significance of IgE in a large cohort of patients with moderate or severe chronic graft-versus-host disease.

Authors:  Sencer Goklemez; Filip Pirsl; Lauren M Curtis; Seth M Steinberg; Edward W Cowen; Jacqueline W Mays; Meg Kenyon; Judy Baruffaldi; Fran T Hakim; Steven Z Pavletic
Journal:  Am J Hematol       Date:  2017-06-01       Impact factor: 10.047

3.  In vitro stimulation of IgE production at a single precursor level by human alloreactive T helper clones.

Authors:  A Lanzavecchia; B Parodi
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

4.  Functional and morphological suppressor T cell deficit in acute GVHD.

Authors:  F Di Padova; A Gratwohl; M Corneo; B Speck
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

5.  Eosinophils in the blood of hematopoietic stem cell transplanted patients are activated and have different molecular marker profiles in acute and chronic graft-versus-host disease.

Authors:  Julia Cromvik; Marianne Johnsson; Krista Vaht; Jan-Erik Johansson; Christine Wennerås
Journal:  Immun Inflamm Dis       Date:  2014-07-07

6.  The Pholcodine Case. Cough Medicines, IgE-Sensitization, and Anaphylaxis: A Devious Connection.

Authors:  E Florvaag; S G O Johansson
Journal:  World Allergy Organ J       Date:  2012-07       Impact factor: 4.084

7.  Pholcodine consumption and immunoglobulin E-sensitization in atopics from Australia, Korea, and Japan.

Authors:  Constance H Katelaris; Motohiro Kurosawa; Hee-Bom Moon; Magnus Borres; Erik Florvaag; Stig Gunnar Olof Johansson
Journal:  Asia Pac Allergy       Date:  2014-04-29

8.  National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution.

Authors:  Anita Lawitschka; Ece Dila Gueclue; Angela Januszko; Ulrike Körmöczi; Arno Rottal; Gerhard Fritsch; Dorothea Bauer; Christina Peters; Hildegard T Greinix; Winfried F Pickl; Zoya Kuzmina
Journal:  Front Immunol       Date:  2019-08-27       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.